Martin Linde (born 1971) has been chairman of AcouSort’s board since 2015. He holds a M.Sc. degree in Business and Administration and an EMBA, both degrees are from Lund University in Sweden.
Martin Linde has vast industry experience and has been CEO for Arc Aroma Pure AB, Atria Retail, Aqilles Invest AB and several other companies. He holds board assignments in several listed companies as Optifreeze AB, Carbiotix AB, Biofrigas AB, LifeAssays AB and some not listed as Thyrolytics and family companies. His focal points have included strategy, commercialization, sales & marketing and financing.
Martin Linde owns 2.95% of the capital share and represents 2.95% of the votes in AcouSort.
Thomas Laurell (born 1961) is Professor of Medical Chemical Microsensors at the Dept. of Biomedical Engineering at Lund University and a Swedish Research Council Distinguished Professor. He is also Fellow at the School of Engineering, The University of Tokyo and Distinguished Professor, Dongguk University, Seoul, Republic of Korea. Professor Laurell is a world leader within the field of acoustophoresis based on microchips. He has published more than 130 academic articles and made 25 patent applications.
Professor Laurell has a solid commercial background and has been involved in a number of businesses, including ErySave AB, Picology AB and ISET AB. He holds a board assignment in Genovis AB. Besides his academic and commercialization experience, Professor Laurell has been recognized with prizes within academia, innovation and entrepreneurship. The research that AcouSort is based on comes from Professor Laurell’s group at Lund University.
Thomas Laurell owns 10.76% of the capital share and represents 10.76% of the votes in AcouSort.
Stefan Scheding (born 1962) is Professor, Senior Consultant at Lund Stem Cell Center at Lund University Faculty of Medicine & University Hospital Lund. Stefan Scheding holds a Doctor of Medicine (MD) from the University of Cologne. Dr. Scheding is group leader at Lund’s Stem Cell Center at Lunds University hospital focusing on developing new types of cell therapies for stem cell transplantations. Dr. Scheding is involved in a number of national and international research committes for blood cancer and cell therapy and has published over 80 publications in this field.
Stefan Scheding owns 8.68% of the capital share and represents 8.68% of the votes in AcouSort.
Kristian Enkvist has over 20 years of international industrial experience in R&D, business development and product portfolio management in medical equipment, diagnostics and Life Science industries (HemoCue, Gambro, PerkinElmer, Wallac). Prior to this, Kristian worked in Big Pharma with early drug discovery (Astra Zeneca). He holds a PhD in biochemistry and is a Docent in neurochemistry at Åbo Academy University. Kristian was the CEO of AcouSort AB 2012-2014. He is currently the CEO of e-health startup company POOW Applications AB, senior advisor at SmiLe Life Science Incubator in Lund, and Chairman of the Board at Norinvent AB (Publ).
Kristian does not own any AcouSort shares.